The RNA-binding protein QKI suppresses cancer-associated aberrant splicing

Area of Science:

• Molecular Biology
• Oncology
• RNA Splicing

Background:

• Lung cancer is a leading cause of cancer mortality globally.
• Aberrant RNA splicing is implicated in lung tumorigenesis, but regulatory mechanisms remain unclear.
• Understanding splicing regulation is crucial for developing novel lung cancer therapies.

Purpose of the Study:

• To identify key regulators of alternative splicing in lung cancer.
• To investigate the role of the RNA-binding protein QKI in lung cancer.
• To elucidate the functional consequences of QKI down-regulation in lung tumorigenesis.

Main Methods:

• Quantitative analysis of QKI expression in lung cancer tissues.
• In vitro and in vivo assays to assess QKI-5's effect on cancer cell proliferation and transformation.
• RNA immunoprecipitation and splicing assays to identify QKI target genes and mechanisms.
• Analysis of the Notch signaling pathway activation.

Main Results:

• QKI is frequently down-regulated in lung cancer, correlating with poorer patient prognosis.
• QKI-5 significantly inhibits lung cancer cell proliferation and transformation.
• QKI-5 regulates the alternative splicing of NUMB, suppressing cell proliferation and Notch pathway activation.
• QKI-5 inhibits splicing by competing with SF1 for branchpoint sequence binding.

Conclusions:

• QKI is a critical regulator of alternative splicing in lung cancer.
• QKI-5 acts as a tumor suppressor by modulating NUMB splicing and the Notch pathway.
• QKI represents a novel therapeutic target for lung cancer treatment.